AbbVie has been granted a patent for a method of treating active psoriatic arthritis by administering a tablet containing a specific compound once daily. The compound, (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, is administered in a 15 mg dose. GlobalData’s report on AbbVie gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AbbVie, Peptide pharmacophores was a key innovation area identified from patents. AbbVie's grant share as of May 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of psoriatic arthritis with tablet containing compound 1
A recently granted patent (Publication Number: US11993605B2) discloses a method for treating active psoriatic arthritis in human patients. The method involves orally administering a tablet containing a specific compound, (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1), at a therapeutically effective amount of 15 mg once daily. This treatment is intended for adult patients who have shown inadequate response or intolerance to disease-modifying antirheumatic drugs, methotrexate, or anti-TNF biologic agents.
Furthermore, the patent claims that administering the specified compound at the mentioned dosage results in significant clinical responses. The method aims to achieve an ACR70, ACR50, or ACR20 response at 12 weeks after the initial daily administration of the tablet. These responses indicate varying levels of improvement in the patient's condition, with the ACR70 response being the most substantial. The compound is administered in the form of 15.4 mg of Freebase Hydrate Form C, ensuring optimal therapeutic efficacy in treating active psoriatic arthritis in patients who have not responded well to conventional treatments.
To know more about GlobalData’s detailed insights on AbbVie, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
